AnaptysBio (ANAB) vs Korsana Biosciences (KRSA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
AnaptysBio (ANAB) has outperformed Korsana Biosciences (KRSA) over the past year, gaining 117.8% versus a gain of 90.0%. Over five years, ANAB leads with a +141.8% price change compared with -91.1% for KRSA. Korsana Biosciences is the larger company by market cap ($1.53 billion vs $1.38 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ANAB | KRSA |
|---|---|---|
| Share price | $46.21 | $33.51 |
| Market cap | $1.38B | $1.53B |
| 1-day change | +1.23% | +6.37% |
| YTD return | +42.98% | +276.94% |
| 1-year return | +117.77% | +89.97% |
| 5-year return | +141.77% | -91.10% |
| Forward P/E | 9.12 | — |
| EPS (TTM) | $-0.96 | $-7.07 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $72.36 | $59.36 |
| 52-week low | $20.18 | $7.19 |
| Distance from 52-week high | -36.14% | -43.55% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +88.81% | +31.30% |
| Average volume | 563.32K | 32.06K |
| Shares outstanding | 29.90M | 45.54M |
| Employees | — | 19 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ANAB has outperformed KRSA by 27.8 percentage points over the past year.
About AnaptysBio
ANAB stock →AnaptysBio, Inc. discovers and out-licenses therapeutic bodies in the United States.
Health Care · Biotechnology: Pharmaceutical Preparations
About Korsana Biosciences
KRSA stock →Korsana Biosciences, Inc. develops therapeutic antibodies for the treatment of neurodegenerative diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 19 employees
ANAB vs KRSA FAQ
Which is bigger, AnaptysBio or Korsana Biosciences?
Korsana Biosciences (KRSA) is larger, with a market capitalization of $1.53B compared with $1.38B for AnaptysBio (ANAB).
Which stock has performed better over the past year, ANAB or KRSA?
ANAB returned +117.77% over the past 12 months, compared with +89.97% for KRSA (price return, excluding dividends). Past performance does not predict future results.
Are AnaptysBio and Korsana Biosciences in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.